Dermata Therapeutics Warrant Stock Today
Dermata Therapeutics is selling for under 0.0088 as of the 22nd of November 2024; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.0088. Equity ratings for Dermata Therapeutics Warrant are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of December 2022 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of August 2021 | Category Healthcare | Classification Health Care |
Valuation Profit Patterns
Check how we calculate scores
Dermata Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Dermata Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dermata Therapeutics' financial leverage. It provides some insight into what part of Dermata Therapeutics' total assets is financed by creditors.
| |||||
Dermata Therapeutics Warrant (DRMAW) is traded on NASDAQ Exchange in USA. It is located in 3525 Del Mar Heights Road, San Diego, CA, United States, 92130 and employs 8 people. Dermata Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Dermata Therapeutics generates negative cash flow from operations
Check Dermata Therapeutics Probability Of Bankruptcy
Dermata Therapeutics Historical Income Statement
Dermata Stock Against Markets
Dermata Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dermata Therapeutics stock to make a market-neutral strategy. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Dermata Therapeutics Corporate Management
| Mr MPH | VP Devel | Profile | |
| Maria MBA | Senior Assurance | Profile | |
| Gerald Proehl | Chairman, CoFounder | Profile | |
| Kyri Hoose | VP CFO | Profile | |
| Sean Proehl | Senior Development | Profile | |
| Dr MPH | Senior Officer | Profile |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.